Drugs in MeSH Category Adrenergic alpha-2 Receptor Antagonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-002	Oct 28, 2010	AB	RX	Yes	No	8,883,794*PED				Y
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-002	Oct 28, 2010	AB	RX	Yes	No	9,907,794*PED				Y
Jubilant Generics	LURASIDONE HYDROCHLORIDE	lurasidone hydrochloride	TABLET;ORAL	210388-005	Dec 6, 2024	AB	RX	No	No
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-003	Dec 7, 2011	AB	RX	Yes	No	8,883,794*PED				Y
Jubilant Generics	LURASIDONE HYDROCHLORIDE	lurasidone hydrochloride	TABLET;ORAL	210388-002	Dec 6, 2024	AB	RX	No	No
Watson Labs Teva	LURASIDONE HYDROCHLORIDE	lurasidone hydrochloride	TABLET;ORAL	208016-001	Feb 2, 2021		DISCN	No	No
Heritage Pharma Avet	LURASIDONE HYDROCHLORIDE	lurasidone hydrochloride	TABLET;ORAL	208058-001	Sep 4, 2019	AB	RX	No	No

Adrenergic alpha-2 Receptor Antagonists Market Analysis and Financial Projection

The market dynamics and patent landscape for adrenergic alpha-2 receptor antagonists reveal a niche but evolving sector within the pharmaceutical industry, driven by therapeutic innovation and expanding applications. Here's a comprehensive analysis:

---

Market Dynamics

Growth Projections and Drivers

• The alpha-2 adrenergic antagonist market is indirectly influenced by broader trends in adrenergic drug development. While direct market figures for antagonists are less prominent, related segments like the yohimbine market (a well-known alpha-2 antagonist) are anticipated to grow due to increasing use in dietary supplements and off-label applications for depression and anxiety[17].
• Key therapeutic areas driving demand include:
  • Mental health: Alpha-2 antagonists like idazoxan XR are under investigation for schizophrenia[18], with companies like Terran Biosciences advancing clinical trials.
  • Veterinary medicine: Antagonists such as atipamezole are critical for reversing sedation caused by alpha-2 agonists like dexmedetomidine[14].
  • Ophthalmology: Research highlights their neuroprotective potential in glaucoma by modulating NMDA receptor function[3].

Regional Insights

• North America dominates due to robust R&D activity and high prevalence of mental health disorders[5][17]. For example, ~8.7 million U.S. adults have ADHD, a condition historically treated with alpha-2 antagonists like guanfacine[5].
• Asia-Pacific shows growth potential, driven by rising hypertension rates (15–35% in urban populations) and increasing healthcare investments[5][12].

Challenges

• Side effects: Sedation, hypotension, and dizziness limit broader clinical adoption[5][17].
• Regulatory hurdles: Restrictions on yohimbine in some regions due to safety concerns[17].
• Competition: Alternative therapies, including non-pharmacological interventions, challenge market penetration[5].

---

Patent Landscape

Recent Innovations

• ADRA2A Antagonists: Structure-activity studies on yohimbine derivatives (e.g., compound 4n) have yielded selective antagonists with 556-fold selectivity for ADRA2A over ADRA2B receptors[4].
• Analgesic Formulations: Patent US20230372309A1 covers compositions using alpha-2 antagonists for pain management, emphasizing reduced opioid reliance[9][13].
• Neuroprotection: Patents like US10668094B2 target Na,K-ATPase inhibitors to lower intraocular pressure, leveraging alpha-2 receptor interactions[2].

Strategic Acquisitions

• Companies like Terran Biosciences are acquiring patent portfolios to advance CNS drugs. For example, their exclusive rights to idazoxan XR for schizophrenia highlight a focus on late-stage clinical assets[18].
• Legal disputes, such as Terran’s lawsuit against COMPASS Pathways over psilocybin-related IP, underscore the competitive nature of neuropharmacology patents[18].

---

Key Players and Trends

Company/Entity	Focus Area	Notable Activity
Pfizer/Merck	Broad adrenergic drug pipeline	Investing in agonist-antagonist combos[5]
Terran Biosciences	CNS disorders	Developing idazoxan XR for schizophrenia[18]
Boehringer Ingelheim	Neuroprotection	Exploring NMDA receptor modulation[3]

Emerging Trends

• Precision Medicine: AI-driven drug discovery is accelerating the development of subtype-selective antagonists (e.g., ADRA2A vs. ADRA2B)[4][8].
• Combination Therapies: Pairing alpha-2 antagonists with psychedelics (e.g., psilocybin) to enhance therapeutic outcomes[18].

---

Future Outlook

• The market is poised for 5.5–8.7% CAGR through 2033, fueled by unmet needs in mental health and chronic disease[5][12].
• Patent Expirations: Expiry of key patents (e.g., US10668094B2 in 2024) may open opportunities for generics[2].
• Innovation Hotspots: Focus on reducing off-target effects (e.g., alpha-2C receptor selectivity) and improving bioavailability[4][9].

“Alpha-2 antagonists are transitioning from veterinary reversal agents to groundbreaking CNS therapeutics, with neuroprotection and neuromodulation as key frontiers.” [3][9]

---

This sector’s growth hinges on overcoming tolerability issues and leveraging technological advancements in drug design. Strategic patent filings and partnerships will remain critical for market leadership.

References

1. https://sites.google.com/view/real-timebusinessresearchinsig/reports/alpha2-adrenergic-agonist-market
2. https://patents.google.com/patent/US10668094B2/en
3. https://pubmed.ncbi.nlm.nih.gov/18566471/
4. https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c00323
5. https://www.researchnester.com/reports/alpha-2-receptor-agonists-market/3265
6. https://www.drugpatentwatch.com/p/patent/6673337
7. https://pubmed.ncbi.nlm.nih.gov/17266605/
8. https://github.com/jugutstam/Market-Research-Report-List-1/blob/main/a2-adrenergic-agonist-market.md
9. https://patents.google.com/patent/US20230372309A1/en
10. https://pubmed.ncbi.nlm.nih.gov/18579700/
11. https://www.aoa.org/assets/documents/EBO/CRG%20-%20GLAUCOMA%204/934-003ARTHUR2011.pdf
12. https://www.verifiedmarketreports.com/product/alpha-2-adrenergic-agonist-market/
13. https://patents.google.com/patent/US20230372309A1/fr
14. https://en.wikipedia.org/wiki/Alpha-2_blocker
15. https://karger.com/nen/article/39/3/275/222353/Role-of-Alpha1-and-Alpha2-Adrenergic-Receptors-in
16. https://pubmed.ncbi.nlm.nih.gov/9399373/
17. https://www.alliedmarketresearch.com/yohimbine-market-A13573
18. https://psychedelicalpha.com/news/analysis-patent-applications-provide-hints-at-terran-biosciences-strategy